The Seed Investor News Roundup

Biosynthesis: Unlocking the Medical Potential of Cannabis

View the infographic on how Biosynthesis could unlock the full medical potential of Cannabis, unlocking massive market potential.

Read the Investors Guide To Newly Emerging Marijuana Markets

LEARN MORE

Dangerous Opioid Side Effects Shifts Market Focus to Cannabis for Chronic Pain

The need for alternatives like cannabinoid-based therapies is generating significant market interest for prospective solution developers such as InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)

Aurora Cannabis and CannaRoyalty Sign Letter of Intent for International Drug Delivery Technology Agreement

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) today announced that the companies have signed a binding Letter of Intent, giving Aurora the exclusive right for 90 days to negotiate a final licensing agreement.

Maricann Group Inc. Announces $20 Million Private Placement

Expansion Will Allow up to 95,000 kg of Dry Flower Production Capacity.

Aphria Inc. Announces $100 Million Bought Deal

Aphria Inc. (TSX:APH) is pleased to announce that it has entered into an agreement with Clarus Securities Inc., on behalf of a syndicate of underwriters pursuant to which the Underwriters have agreed to purchase, on a "bought deal" basis, 7,272,740 Common Shares of the Company at a price of C$13.75 per Common Share for aggregate gross proceeds to the Company of C$100,000,175.

Liberals reach deal with the provinces on sharing pot tax revenue, with price pegged at about $10 a gram

Agreement gives provinces 75% of tax revenues from legal cannabis sales, caps federal share at $100M

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed investment advisor.

TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260

info@theseedinvestor.com

To keep receiving emails from us, please add us to your address book.